Topic: lung disease

Less than two years after jumping ship from the FDA to AstraZeneca, Badrul Chowdhury, M.D., Ph.D., is leaving the Big Pharma.

Shionogi and Hsiri Therapeutics first joined forces last year in a licensing and R&D deal focused on tuberculosis and non-tuberculous lung infections.

The partners will work out of a joint lab at Brigham and Women's Hospital in Boston that will receive more than $30 million over the next five years.

Ritu Lal co-founded GEn1E alongside Clint Webb in 2018, licensing a group of p38alpha kinase inhibitors from the University of Maryland, Baltimore.

Boehringer Ingelheim is licensing an autotaxin inhibitor from Bridge Biotherapeutics for €45 million and promising more than €1 billion in biobucks.

Lung Therapeutics has raised a $36 million series C round to take a treatment for a serious complication of pneumonia through phase 2 studies.

The study linked QVM149 to statistically significant improvements in lung function, leading Novartis to talk up its mooted blockbuster. 

The FDA has approved a device system that flushes and oxygenates the donated organ once its outside of the body, while washing it in a preservative.

Scientists from the Children’s Hospital of Philadelphia and UPenn have used CRISPR gene editing to prevent a lung disease in mice before birth.

Paul Streck, M.D., will this week exit his role as chief medical officer of Insmed to “pursue an employment opportunity on the West Coast.”